Citation Impact
Citing Papers
Modern treatment of haemophilia.
1995
A Multicenter Study of Recombinant Factor VIII (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A
1994
Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
2020
Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach
2023 StandoutNobel
How long do nosocomial pathogens persist on inanimate surfaces? A systematic review
2006 Standout
Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces
2004
Non‐genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report
2010
Lipid nanoparticles for mRNA delivery
2021 Standout
In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application
2016
Isolation of Infectious Cystic Fibrosis Patients: Results of a Systematic Review
2005
Factor VIII inhibitors in mild and moderate‐severity haemophilia A
1998
A Review of the Research Literature on Evidence-Based Healthcare Design
2008 Standout
The epidemiology of inhibitors in haemophilia A: a systematic review
2003
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
2001 Standout
Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery
2021 StandoutNobel
Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A
2003
Aptamers as therapeutics
2010 Standout
Emerging roles of protein mannosylation in inflammation and infection
2016
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Factor IX Inhibitors and Anaphylaxis in Hemophilia B
1997
Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors
1993
Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening
2003
Infection Control Recommendations for Patients With Cystic Fibrosis: Microbiology, Important Pathogens, and Infection Control Practices to Prevent Patient-to-Patient Transmission
2003
Immunogenicity of protein therapeutics
2007
Protein therapeutics: a summary and pharmacological classification
2007 Standout
The molecular mechanisms of immunomodulation and tolerance induction to factor VIII
2009
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
2003 Standout
Glycoproteomics
2022 StandoutNobel
How I treat age-related morbidities in elderly persons with hemophilia
2009
The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability
1995
Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission
2003
Ionizable lipid nanoparticles for in utero mRNA delivery
2021 StandoutNobel
2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings
2007 Standout
ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor
2009
Guidelines for the management of hemophilia
2012 Standout
Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction
1993
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes
2014 StandoutNobel
Works of B. Krackhardt being referenced
Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
1992
Risk of Pseudomonas aeruginosa cross-colonisation in patients with cystic fibrosis within a holiday camp--a molecular-epidemiological study.
2000